Top Markets
#1 Pleasing Gold Pleasing Gold +1,498.13%
#2 PulseChain PulseChain +58.12%
#3 Merlin's Seal BTC Merlin's Seal BTC +33.53%
#4 BOOK OF MEME BOOK OF MEME +29.96%
#5 Ontology Gas Ontology Gas +28.98%
#6 Neiro Neiro +24.50%
#7 ConstitutionDAO ConstitutionDAO +24.22%
#8 Unit Pump Unit Pump +20.90%
#9 Pump.fun Pump.fun +20.90%
#10 DogBull DogBull +19.72%
Coin of the day
Pleasing Gold Pleasing Gold
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc.

ARPO
Kedudukan dalam Saham #26438
Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in... Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.
Harga Saham
$2.20
Disegerakkan terakhir: 2021-08-26
Modal Pasaran
$40.53M
Perubahan (1 hari)
-0.90%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Aerpio Pharmaceuticals, Inc. (ARPO)

Kategori

Healthcare
Nisbah P/E bagi Aerpio Pharmaceuticals, Inc. (ARPO)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Aerpio Pharmaceuticals, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Aerpio Pharmaceuticals, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.